Statement of Significance
Narcolepsy, narcolepsy, daytime sleepiness
NARCOLEPSY, NARCOLEPSY WITHOUT CATAPLEXY, NARCOLEPSY, NARCOLEPSY AND CATAPLEXY, NARCOLEPSY TYPE 1, NARCOLEPSY WITH CATAPLEXY
Narcolepsy is classified into two subtypes: narcolepsy type 1 (NT1), or narcolepsy with cataplexy, and narcolepsy type 2 (NT2), or narcolepsy without cataplexy. The etiology of NT2 is not well understood, and limited published data are available on the benefits of treatment specific to NT2, as trials have historically enrolled patients with narcolepsy with cataplexy or unspecified narcolepsy. A recently approved extended-release once-nightly sodium oxybate (ON-SXB) demonstrated effectiveness for treating excessive daytime sleepiness in adults with narcolepsy and cataplexy in patients with NT1. Results from post hoc analyses of the phase 3 REST-ON trial demonstrated consistent efficacy of ON-SXB in patients regardless of narcolepsy type. ON-SXB is the only once-at-bedtime oxybate treatment option for people with either narcolepsy type.